Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | VCP | P55072 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740991 | 1.00 | HRH1 (0.42) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL15740987 | 1.00 | HRH1 (0.42) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4371441 | 0.93 | HRH1 (0.44) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10339339 | 0.85 | HRH1 (0.42) | HRH1SLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL22859969 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4ALDH1A1RAB9A | |
| SCHEMBL1930886 | 0.79 | HRH1 (0.41) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11503080 | 0.79 | LTA4H (0.43) | HRH1SLC6A2SLC6A3SLC6A4RAB9A | |
| SCHEMBL791816 | 0.78 | HRH1 (0.63) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11792902 | 0.78 | HRH1 (0.63) | HRH1VCPSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL22828358 | 0.77 | ALDH1A1 (0.46) | ALDH1A1RAB9AFAAHNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245744-A2 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2023-09-20 | — | — | EP | disclosed |
| EP-2922574-B1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B V (NL) | 2023-05-17 | — | — | EP | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-01-07 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| EP-2922574-A1 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081301-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081300-A1 | CHANNEL PROTEIN ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081299-A1 | ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | HRH1 442/4885VCP 1599/4885SLC6A2 4461/4885 |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | HRH1 454/4885VCP 1310/4885SLC6A2 4420/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | HRH1 454/4885VCP 1310/4885SLC6A2 4420/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | HRH1 349/4885VCP 3781/4885SLC6A2 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.